Lilly to Acquire Calytrix for Up to $1.5 Bn in Cash

Lilly to Acquire Calytrix for Up to $1.5 Bn to Expand Rare Blood Cancer Pipeline

Lilly to Acquire Calytrix for Up to $1.5 Bn to Expand Rare Blood Cancer Pipeline

Lilly will make an upfront payment to Calytrix, followed by additional payments linked to clinical development and regulatory milestones.

Eli Lilly has agreed to acquire privately held Massachusetts-based biotechnology company Calytrix Bio for up to $1.5 Bn in cash, strengthening its efforts to develop treatments for rare blood cancers.

The transaction will bring an experimental antibody candidate targeting disease-causing genetic alterations into Lilly’s drug development pipeline.

Lilly’s existing portfolio includes Jaypirca, a US Food and Drug Administration (FDA)-approved medicine used to treat certain blood cancers. Earlier in 2026, the company also acquired Ajax Therapeutics for $2.3 Bn, adding another potential treatment for blood cancer to its development pipeline.

Under the latest agreement, Lilly will make an upfront payment to Calytrix, followed by additional payments linked to clinical development and regulatory milestones.

The companies have not disclosed the upfront amount or the expected closing date of the transaction. The total consideration could reach $1.5 Bn if the specified milestones are achieved.

Calytrix’s lead candidate is an experimental antibody treatment being developed for essential thrombocythemia and myelofibrosis, two rare disorders involving abnormal blood cell production in the bone marrow. The candidate remains at an early stage and has not yet entered human clinical trials.

The investigational drug targets mutated calreticulin, a protein alteration associated with the development of these conditions. According to Calytrix, the treatment is designed to recognise and attack abnormal cells responsible for driving the disease while preserving healthy blood-forming cells. Its potential effectiveness and safety will need to be established through clinical testing.

Existing treatments for these disorders primarily focus on controlling symptoms and reducing complications. An approach that directly targets disease-driving cells could offer a different treatment strategy, although its clinical benefits remain unproven.

Calytrix is based in Wellesley Hills, Massachusetts, and was founded by J.P. Morgan Life Sciences Private Capital, the venture capital arm of J.P. Morgan Asset Management. Its investors include Westlake BioPartners and Avoro Ventures.

The acquisition adds to Lilly’s broader investment in oncology and specialist medicines as pharmaceutical companies continue to pursue experimental therapies for conditions with significant unmet medical needs.

Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All

Welcome back.

Pick up where you left off on Digital Health News.

Sign in to DHN

For existing DHN and DHN Plus members.

or
Continue with Google
New to DHN?